Rapport Therapeutics, Inc.
RAPP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002012593
In the last 90 days, Rapport Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $2.13B in total; no superinvestor holds it.
Holders of 5% or more of RAPP
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Rapport Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 13G | 19.50%7.14M shares | New | Feb 13, 20251 filing | Feb 13, 2025 | SEC |
| Cormorant Asset Management, LP | 13G/A | 6.35%3.03M shares | −0.35 ppfrom 6.70% | Nov 14, 20252 filings | Feb 17, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.03%2.40M shares | New | Jan 21, 20261 filing | Jan 21, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
6 Schedule 13D and 13G filings on Rapport Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 20263:02 PM ET | Cormorant Asset Management, LPand 1 other | 13G/A | 6.35%3.03M shares | −0.35 ppfrom 6.70% | Dec 31, 2025 | SEC |
| Jan 21, 202612:30 PM ET | BlackRock, Inc. | 13G | 5.03%2.40M shares | New | Dec 31, 2025 | SEC |
| Nov 14, 20251:09 PM ET | Cormorant Asset Management, LPand 1 other | 13G/A | 6.70%3.19M shares | – | Sep 30, 2025 | SEC |
| Oct 22, 20255:09 PM ET | Johnson & Johnsonand 1 other | 13G/A | 4.90%1.78M shares | –Below 5% | Sep 30, 2025 | SEC |
| Sep 18, 20255:32 PM ET | Sofinnova Venture Partners XI, L.P.and 4 others | 13D/A | 4.20%1.95M shares | –Below 5% | Sep 11, 2025 | SEC |
| Feb 13, 20254:15 PM ET | Third Rock Ventures V, L.P.and 5 others | 13G | 19.50%7.14M shares | New | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Rapport Therapeutics, Inc. shares.
No Form 144 notices for Rapport Therapeutics, Inc. are on file.